SIMRIS GROUP AB Following the successful acquisition of
Relaunch of food supplements in Q4’22
With the structural foundation in place, Simris is now on track to exploit the three most promising verticals in the microalgae and cyanobacteria space. In December, Simris will relaunch its microalgae-based Food Supplement products. This time, however, the capsules will contain twice the EPA and DHA compared to previous products, and even so they will be half the size – which makes them easier to swallow, an important factor for consumers when making a purchase decision. They will also have more efficient packaging and a more competitive price. The launch will begin with
Three drivers for revenue growth in 2023
Over the past two years, the recently acquired Cyano Biotech had an average turnover of over
However, the relaunch of food supplements is likely to increase costs during launch phase Q4/Q1, while the optimized production of Fucoxanthin and new B2B business will impact revenues in Q2’23 at the earliest. Along with the lower-than-expected revenue in Q3’22, we’ve made a downwards revision of our sales forecast for FY 2022 and FY 2023 to
Significant revaluation potential
One of the challenges for Simris historically has been how to allocate its limited resources to best capitalize on all the various and highly dispersed business opportunities that come with owning a world class microalgae production facility. But now we’re getting a clearer view on how management plans to capture the best opportunities, with a clear plan and roadmap for each vertical, focusing on the most high-value opportunities in each field. This is also the strategy likely to produce the most value for shareholders in the long-term.
All in all, we continue to see a significant revaluation potential in Simris. With only a fraction of listed peer multiples, we find support for a fair value of
Read the full report on
© Modular Finance, source
